Compare Indivior Pharmaceuticals Inc. Common Stock (INDV) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indivior Pharmaceuticals Inc. Common Stock vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Indivior Pharmaceuticals Inc. Common Stock trades at $34.71 (market cap $4.03B), while Vanguard Intermediate Term Corporate Bond ETF trades at $79.06 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is far larger — about 17.9× Indivior Pharmaceuticals Inc. Common Stock's market cap, and Indivior Pharmaceuticals Inc. Common Stock is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Indivior Pharmaceuticals Inc. Common Stock for 0 Days and Vanguard Intermediate Term Corporate Bond ETF for 64 Days on average.
| INDV | VCIT | |
|---|---|---|
Market Cap | $4.03B | $72.20B |
Volume | 2,781,171 | 13,245,117 |
Sector | Health | Fixed Income |
52-Week High | $41.83 | $84.82 |
52-Week Low | $24.09 | $77.98 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $4.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VCIT trades at $79.07, up 0.75% with a bearish technical signal from moving averages. The ETF offers a 4.8% yield with a 6-year duration, positioning it as a balanced income option among corporate bond ETFs. Recent institutional buying from Engineers Gate Manager LP and HB Wealth Management reflects confidence in intermediate-term corporate credit. Technical indicators show RSI_6 at overbought levels while RSI_12 remains neutral.
The outlook remains favorable for income investors seeking corporate bond exposure with Vanguard's low 0.03% expense ratio advantage. Key risks include interest rate sensitivity and credit spread volatility. Current support sits at $78 with resistance at $79, suggesting limited near-term price movement potential despite the attractive yield profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Indivior Pharmaceuticals Inc. Common Stock
Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.
Read more on INDV →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
